157 related articles for article (PubMed ID: 35228399)
1. Risk Factors of Proteinuria in Patients with Hepatocellular Carcinoma Receiving Lenvatinib.
Ikesue H; Yamamoto H; Hirabatake M; Hashida T; Chung H; Inokuma T; Muroi N
Biol Pharm Bull; 2022; 45(3):333-338. PubMed ID: 35228399
[TBL] [Abstract][Full Text] [Related]
2. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma.
Ikeda K; Kudo M; Kawazoe S; Osaki Y; Ikeda M; Okusaka T; Tamai T; Suzuki T; Hisai T; Hayato S; Okita K; Kumada H
J Gastroenterol; 2017 Apr; 52(4):512-519. PubMed ID: 27704266
[TBL] [Abstract][Full Text] [Related]
3. The efficacy and safety of lenvatinib for advanced hepatocellular carcinoma in a real-world setting.
Obi S; Sato T; Sato S; Kanda M; Tokudome Y; Kojima Y; Suzuki Y; Hosoda K; Kawai T; Kondo Y; Isomura Y; Ohyama H; Nakagomi K; Ashizawa H; Miura Y; Amano H; Mochizuki H; Omata M
Hepatol Int; 2019 Mar; 13(2):199-204. PubMed ID: 30671808
[TBL] [Abstract][Full Text] [Related]
4. Association Between Renal Adverse Effects and Mortality in Patients With Hepatocellular Carcinoma Treated With Lenvatinib.
Shimamura Y; Abe K; Maeda T; Matsui T; Ishiguro A; Takizawa H
In Vivo; 2021; 35(3):1647-1653. PubMed ID: 33910848
[TBL] [Abstract][Full Text] [Related]
5. Impact of lenvatinib on renal function compared to sorafenib for unresectable hepatocellular carcinoma.
Sasaki R; Fukushima M; Haraguchi M; Honda T; Miuma S; Miyaaki H; Nakao K
Medicine (Baltimore); 2022 May; 101(19):e29289. PubMed ID: 35583540
[TBL] [Abstract][Full Text] [Related]
6. Clinical importance of muscle volume in lenvatinib treatment for hepatocellular carcinoma: Analysis adjusted with inverse probability weighting.
Hiraoka A; Kumada T; Kariyama K; Tada T; Tani J; Fukunishi S; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Kawata K; Yasuda S; Toyoda H; Ohama H; Nouso K; Tsutsui A; Nagano T; Itokawa N; Hayama K; Arai T; Imai M; Koizumi Y; Nakamura S; Joko K; Michitaka K; Hiasa Y; Kudo M;
J Gastroenterol Hepatol; 2021 Jul; 36(7):1812-1819. PubMed ID: 33171524
[TBL] [Abstract][Full Text] [Related]
7. ALBI Grade Is a Predictive Factor of Lenvatinib Treatment Discontinuation due to Adverse Events in Hepatocellular Carcinoma.
Enomoto D; Yamamoto K; Matsumoto Y; Morioka A; Omura T; Komatsu S; Yano Y; Fukumoto T; Yano I
Anticancer Res; 2023 Mar; 43(3):1317-1323. PubMed ID: 36854508
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions-Multicenter analysis.
Hiraoka A; Kumada T; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Kariyama K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Tada T; Toyoda H; Nouso K; Tsutsui A; Nagano T; Itokawa N; Hayama K; Imai M; Joko K; Koizumi Y; Hiasa Y; Michitaka K; Kudo M;
Cancer Med; 2019 Jul; 8(8):3719-3728. PubMed ID: 31127698
[TBL] [Abstract][Full Text] [Related]
9. FDA Supplemental Approval Summary: Lenvatinib for the Treatment of Unresectable Hepatocellular Carcinoma.
Nair A; Reece K; Donoghue MB; Yuan WV; Rodriguez L; Keegan P; Pazdur R
Oncologist; 2021 Mar; 26(3):e484-e491. PubMed ID: 33044793
[TBL] [Abstract][Full Text] [Related]
10. Impact of Early Lenvatinib Administration on Survival in Patients with Intermediate-Stage Hepatocellular Carcinoma: A Multicenter, Inverse Probability Weighting Analysis.
Tada T; Kumada T; Hiraoka A; Michitaka K; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Kariyama K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Yasuda S; Toyoda H; Fukunishi S; Ohama H; Kawata K; Nakamura S; Nouso K; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Joko K; Koizumi Y; Hiasa Y;
Oncology; 2021; 99(8):518-527. PubMed ID: 33906189
[TBL] [Abstract][Full Text] [Related]
11. Optimal management of patients with hepatocellular carcinoma treated with lenvatinib.
Ikeda M; Kobayashi M; Tahara M; Kaneko S
Expert Opin Drug Saf; 2018 Nov; 17(11):1095-1105. PubMed ID: 30264594
[TBL] [Abstract][Full Text] [Related]
12. Association of lenvatinib plasma concentration with clinical efficacy and adverse events in patients with hepatocellular carcinoma.
Hata K; Suetsugu K; Egashira N; Makihara Y; Itoh S; Yoshizumi T; Tanaka M; Kohjima M; Watanabe H; Masuda S; Ieiri I
Cancer Chemother Pharmacol; 2020 Dec; 86(6):803-813. PubMed ID: 33095285
[TBL] [Abstract][Full Text] [Related]
13. Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma.
Ikeda M; Okusaka T; Mitsunaga S; Ueno H; Tamai T; Suzuki T; Hayato S; Kadowaki T; Okita K; Kumada H
Clin Cancer Res; 2016 Mar; 22(6):1385-94. PubMed ID: 26500236
[TBL] [Abstract][Full Text] [Related]
14. Clinical impact of proteinuria on renal function and treatment outcomes in patients with radioiodine-refractory thyroid cancer treated with lenvatinib.
Fukuda N; Toda K; Suto H; Oki R; Wang X; Urasaki T; Sato Y; Nakano K; Ono M; Tomomatsu J; Mitani H; Takahashi S
Endocr J; 2024 Apr; 71(4):363-371. PubMed ID: 38296547
[TBL] [Abstract][Full Text] [Related]
15. Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes.
Haddad RI; Schlumberger M; Wirth LJ; Sherman EJ; Shah MH; Robinson B; Dutcus CE; Teng A; Gianoukakis AG; Sherman SI
Endocrine; 2017 Apr; 56(1):121-128. PubMed ID: 28155175
[TBL] [Abstract][Full Text] [Related]
16. Lenvatinib is independently associated with the reduced risk of progressive disease when compared with sorafenib in patients with advanced hepatocellular carcinoma.
Kim S; Kim KH; Kim BK; Park JY; Ahn SH; Kim DY; Kim SU
J Gastroenterol Hepatol; 2021 May; 36(5):1317-1325. PubMed ID: 33217054
[TBL] [Abstract][Full Text] [Related]
17. Impact of lenvatinib on renal function: long-term analysis of differentiated thyroid cancer patients.
Masaki C; Sugino K; Kobayashi S; Hosoi Y; Ono R; Yamazaki H; Akaishi J; Hames KY; Tomoda C; Suzuki A; Matsuzu K; Ohkuwa K; Kitagawa W; Nagahama M; Ito K
BMC Cancer; 2021 Aug; 21(1):894. PubMed ID: 34353305
[TBL] [Abstract][Full Text] [Related]
18. Expert consensus on the management of adverse events in patients receiving lenvatinib for hepatocellular carcinoma.
Kim BH; Yu SJ; Kang W; Cho SB; Park SY; Kim SU; Kim DY
J Gastroenterol Hepatol; 2022 Mar; 37(3):428-439. PubMed ID: 34725855
[TBL] [Abstract][Full Text] [Related]
19. Lenvatinib combined with nivolumab in advanced hepatocellular carcinoma-real-world experience.
Wu WC; Lin TY; Chen MH; Hung YP; Liu CA; Lee RC; Huang YH; Chao Y; Chen SC
Invest New Drugs; 2022 Aug; 40(4):789-797. PubMed ID: 35477812
[TBL] [Abstract][Full Text] [Related]
20. Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinoma.
Kirino S; Tsuchiya K; Kurosaki M; Kaneko S; Inada K; Yamashita K; Osawa L; Hayakawa Y; Sekiguchi S; Okada M; Wang W; Higuchi M; Takaura K; Maeyashiki C; Tamaki N; Yasui Y; Nakanishi H; Itakura J; Takahashi Y; Asahina Y; Izumi N
PLoS One; 2020; 15(4):e0231828. PubMed ID: 32310967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]